Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24508250 | 1.00 | KDM4E (0.47) | KDM4EMAPK1HIF1AEPHX2FAAH | |
| SCHEMBL23696123 | 0.98 | KDM4E (0.48) | KDM4EMAPK1HIF1AEPHX2FAAH | |
| SCHEMBL21106922 | 0.93 | KMT2A (0.40) | KDM4EMAPK1HIF1AEPHX2FAAH | |
| SCHEMBL21107467 | 0.91 | KDM4E (0.57) | KDM4EMAPK1HIF1AFAAHPAOX | |
| SCHEMBL21105774 | 0.91 | KDM4E (0.57) | KDM4EMAPK1HIF1AFAAHPAOX | |
| SCHEMBL22905020 | 0.89 | KDM4E (0.54) | KDM4EMAPK1HIF1AFAAHPAOX | |
| SCHEMBL29307115 | 0.89 | EPHX2 (0.44) | EPHX2FAAHLMNAALDH1A1TSHR | |
| SCHEMBL23559960 | 0.88 | KMT2A (0.50) | EPHX2FAAHLMNAALDH1A1TSHR | |
| SCHEMBL22906477 | 0.88 | FAAH (0.53) | EPHX2FAAHHTTTSHRRECQL | |
| SCHEMBL22790739 | 0.88 | FAAH (0.53) | EPHX2FAAHHTTTSHRRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192586-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023077077-A1 | RNA DEGRADERS AND USES THEREOF | ARRAKIS THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023278759-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2021127278-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021119159-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021011871-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2021011634-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2021011868-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020264490-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020251969-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020251972-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020251971-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885MAPK1 2017/4885HIF1A 3588/4885 |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885MAPK1 2017/4885HIF1A 3588/4885 |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885MAPK1 2017/4885HIF1A 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.